ALKBH5 and osteosarcoma: In osteosarcoma, silencing ALKBH5 increases m6A modifications that destabilize USP22 and RNF40, leading to the downregulation of genes involved in the cell cycle, DNA replication, and repair, whereas enhanced ALKBH5 activity drives USP22/RNF40-dependent oncogenic processes (268).Moreover, USP22 contributes to osteosarcoma progression by modulating glycolytic pathways that affect cell proliferation, apoptosis, migration, and invasion (269).